TD Cowen analyst Yaron Werber maintained a Buy rating on Roivant Sciences (ROIV – Research Report) today. The company’s shares ...

Roivant's high valuation stems from its strong cash position, promising drug pipeline, Techbio assets, and strategic partnerships, making it a compelling buy. Recent sales of Telavant and ...

Strive Enterprises, co-founded by the former Republican presidential candidate, is also launching a wealth management ...

In a report released yesterday, David Risinger from Leerink Partners reiterated a Buy rating on Roivant Sciences (ROIV – Research ...

A substantial insider activity was disclosed on October 23, as Venker, President & COO at Roivant Sciences (NASDAQ:ROIV), reported the exercise of a large sell of company stock options.

Priovant Therapeutics was formed in 2021 through a partnership between Roivant Sciences and Pfizer (NYSE: PFE) with a focus on developing new treatments for rare autoimmune diseases with high ...

Roivant Sciences Ltd. has a 12 month low of $8.47 and a 12 month high of $13.06. The company has a market capitalization of $8.53 billion, a P/E ratio of 2.07 and a beta of 1.24.

This page features the latest news about the Roivant Sciences stock. Roivant Sciences Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, $1.5B Share Buyback Roivant (Nasdaq ...

Jersey City-based Organon has completed its acquisition of Dermavant Sciences Ltd. from Roivant. Dermavant is a company ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Check the time stamp on this data. Updated AI-Generated Signals for Roivant Sciences Ltd. (ROIV) available here: ROIV.